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ABSTRACT: The universally conserved translation elongation factor EF-Tu delivers aminoacyl(aa)-tRNA in the form of an aa-
tRNA·EF-Tu·GTP ternary complex (TC) to the ribosome where it binds to the cognate mRNA codon within the ribosomal A-
site, leading to formation of a pretranslocation (PRE) complex. Here we describe preparation of QSY9 and Cy5 derivatives of the
variant E348C-EF-Tu that are functional in translation elongation. Together with ﬂuorophore derivatives of aa-tRNA and of
ribosomal protein L11, located within the GTPase associated center (GAC), these labeled EF-Tus allow development of two new
FRET assays that permit the dynamics of distance changes between EF-Tu and both L11 (Tu-L11 assay) and aa-tRNA (Tu-
tRNA assay) to be determined during the decoding process. We use these assays to examine: (i) the relative rates of EF-Tu
movement away from the GAC and from aa-tRNA during decoding, (ii) the eﬀects of the misreading-inducing antibiotics
streptomycin and paromomycin on tRNA selection at the A-site, and (iii) how strengthening the binding of aa-tRNA to EF-Tu
aﬀects the rate of EF-Tu movement away from L11 on the ribosome. These FRET assays have the potential to be adapted for
high throughput screening of ribosomal antibiotics.
EF-Tu is, along with EF-G, one of two G-protein factors that
are required for controlling the speed and accuracy with which
the bacterial 70S ribosome, formed by the association of 30S
and 50S subunits, catalyzes polypeptide elongation.1 During an
elongation cycle, a tRNA binds sequentially to several sites in
the 70S ribosome.2 In the ﬁrst elongation cycle, EF-Tu
accelerates the binding of a cognate aminoacyl(aa)-tRNA, in
the form of an aa-tRNA·EF-Tu·GTP ternary complex (TC), to
the ribosomal A/T-site of a 70S initiation complex (70SIC),
which contains initiator fMet-tRNAfMet bound in the ribosomal
P-site. TC binding to the ribosome brings EF-Tu into proximity
with ribosomal protein L11 within the GTPase associated
center (GAC) of the 50S subunit, to which all ribosomal G-
proteins bind.3 Base pairing between the anticodon loop of
cognate aa-tRNA and the three-nucleotide codon in mRNA at
the decoding center of the 30S subunit leads to changes in
ribosome conformation and activation of the EF-Tu GTPase
activity. GTP hydrolysis is followed by Pi release, and
movement of aa-tRNA from the A/T to the A/A site, a
process also known as “accommodation” into the A-site.
Accommodation is rapidly followed by peptide bond formation
within the peptidyl transferase center of the 50S subunit
between fMet-tRNAfMet and aa-tRNA, and EF-Tu·GDP release
from the ribosome, resulting in pretranslocation (PRE)
complex formation. Structural studies show a dramatic
conformational diﬀerence between the GTP- and GDP-bound
forms of EF-Tu.1,4,5 The antibiotic kirromycin inhibits
elongation by “freezing” EF-Tu·GDP on the ribosome in a
GTP-like conformation.6,7
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Selection of the cognate isoacceptor tRNA takes place in two
steps, preceding and following GTP hydrolysis. During initial
selection, all noncognate and the major fraction of near-cognate
TCs dissociate. After GTP hydrolysis, almost all remaining
near-cognate tRNAs are rejected in the so-called proofreading
step; a small fraction goes forward and participates in peptide
bond formation.8−10 The selectivity of the decoding process for
cognate tRNA is reduced by aminoglycoside antibiotics.11,12
Although the movement of tRNA through the ribosome
during decoding has been extensively studied by kinetic,
structural, and modeling studies,6,13−21 the availability of tools
allowing description of the dynamic properties of EF-Tu as it
interacts with both the ribosome and aa-tRNA has been
limited.8,13 Recently, we presented results, most in preliminary
form,20 that an E348C-EF-Tu variant labeled with either the
ﬂuorescence quencher QSY9 or the ﬂuorophore Cy5 could be
used to develop real-time ﬂuorescence resonance energy
transfer (FRET) assays that monitor both EF-Tu contact
with Cy3-labeled aa-tRNA (Tu-tRNA assay)20,22 and proximity
to Cy3-labeled L11 (Tu-L11 assay)20 (Figure 1).
These FRET assays, along with a previously described assay
measuring aa-tRNA movement from the A/T-site to the A-
site,23 permit us to measure the rates of several key substeps of
decoding, including (i) initial TC interaction with the A/T site,
(ii) movement of EF-Tu·GDP away from its initial binding site
during accommodation, and (iii) release of EF-Tu·GDP from
aa-tRNA. Here, we describe the application of these FRET
assays in probing several interesting aspects of the decoding
process, including the formation of stalled complexes, amino-
glycoside antibiotic eﬀects on tRNA misreading, and how
decoding is aﬀected by altering the strength of EF-Tu
interaction with aa-tRNA. The results obtained provide new
insights, reinforce previous observations, and demonstrate the
feasibility of using the FRET assays in high throughput
screening of antibiotics.
■ RESULTS AND DISCUSSION
Nomenclature. The labeled protein synthesis components
employed in this work are named and described in Table 1.
QSY9 is an eﬃcient quencher of Cy3 ﬂuorescence.
Probe-Labeling of E348C-EF-Tu Variants. We used two
E348C EF-Tu variants in this work. The ﬁrst, E348C-EF-Tu,
retains all three endogenous Cys residues (Cys81, Cys137, and
Cys255) and is labeled with either QSY9-maleimide or Cy3-
maleimide, yielding the labeled products denoted EF-TuQSY9
and EF-TuCy3, respectively. EF-TuQSY9 has 1.5 QSY9 residues/
EF-Tu. Wild-type EF-Tu, labeled under identical conditions
and denoted wt-EF-TuQSY9, has 0.5 QSY9/EF-Tu (Supporting
Information Table 1). Similar results are obtained with Cy3
labeling of E348C-EF-Tu (Supporting Information Table 1).
We conclude that Cys348 is much more reactive toward
maleimides than any of the endogenous Cys residues, in line
with its greater solvent accessibility as determined from the
solved EF-Tu structure (PDB 1DG1), and that it can be labeled
essentially to completion under conditions where the other Cys
residues are labeled to only limited extents, approximately 20%
on average. Furthermore, such background labeling is
inconsequential for subsequent EF-Tu:L11 or EF-Tu:tRNA
FRET measurements (Figure 2b and Supporting Information
Figure S1c).
The second variant, C137A/C255V/E348C-EF-Tu, in which
the two nonconserved Cys residues are replaced, is labeled with
Cy5-maleimide, yielding the labeled product denoted EF-
TuAV‑Cy5, which has 0.9 Cy5/EF-Tu, as compared with 0.2
Cy5/EF-Tu for wt-EF-Tu (Supporting Information Table 1),
consistent with earlier results.22
Labeled E348C-EF-Tu Variants Are Functional in TC
Formation and on the Ribosome. EF-TuQSY9 and EF-
TuAV‑Cy5 form tight TCs with Phe-tRNAPhe, denoted TCQSY9
and TCAV‑Cy5, respectively, which are comparable to those
obtained with unlabeled wild-type EF-Tu, as measured by
protection of Phe-tRNAPhe from either RNase A digestion
(TCQSY9, Supporting Information Figure S1a) or from
spontaneous deacylation (TCAV‑Cy5, Supporting Information
Figure S1b). This is in contrast to the weak binding observed in
these assays with the unlabeled triple variant C81S/C137A/
C255V-EF-Tu (EF-TuSAV), a result that is consistent with a
previous study of the functional role of Cys81.24 A more recent
study claimed that aa-tRNA binding to EF-Tu was retained
when Cys81 is replaced by Ala.25 However, in this latter work,
concentrations of both aa-tRNA and EF-Tu were in great
excess over the dissociation constant, so that even compara-
tively large decreases in aﬃnity would not have been detected.
EF-TuQSY9 also shows comparable activity to wt-EF-Tu in
(1) poly(U)-directed poly(Phe) synthesis (76 ± 5% of wt) and
(2) fMetPhe-tRNAPhe formation on rapid mixing of TCQSY9
with 70SIC. Here, the apparent rate constant obtained, 4.5 s−1
Figure 1. Distances between residue numbers 348 (Cα, EF-Tu), 87
(Cα, L11), and 16 (N-1, aminoacyl-tRNA) in a kirromycin- and
paromomycin-stabilized ribosome complex with Thr-tRNAThr bound
in the A/T site. Protein Data Bank accession codes are 2WRN,
2WRO, 2WRQ, and 2WRR.
Table 1. Labeled Protein Synthesis Components
labeled component description
EF-TuQSY9 E348C variant of wt-EF-Tu labeled with QSY9
EF-TuCy3 E348C variant of wt-EF-Tu labeled with Cy3
EF-TuAV‑Cy5 C137A/C255 V/E348C triple variant of EF-Tu
labeled with Cy5
wt-EF-TuQSY9 wt-EF-Tu labeled with QSY9
Phe-tRNAPhe(Cy3) Yeast Phe-tRNAPhe labeled at positions 16/17 with
Cy3
fMet-tRNAfMet(prf) E. coli fMet-tRNAfMet labeled at position 20 with
proﬂavin
TCQSY9 TC containing EF-TuQSY9·GTP and Phe-tRNAPhe
TC QSY9/Cy3 TC containing EF-TuQSY9·GTP and
Phe-tRNAPhe(Cy3)
TCAV‑Cy5 TC containing EF-TuAV‑Cy5·GTP and Phe-tRNAPhe
TCAV‑Cy5/Cy3 TC containing EF-TuAV‑Cy5·GTP and
Phe-tRNAPhe(Cy3)
TCCy3 TC containing EF-Tu·GTP and Phe-tRNAPhe(Cy3)
70SICCy3 70S initiation complex made with ribosomes
containing S87C-L11 labeled with Cy3
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(25 °C), is similar to values reported earlier using unlabeled TC
and 70SIC.8,23
FRET within TCQSY9/Cy3 and TCAV ‑Cy5/Cy3. Phe-
tRNAPhe(Cy3) ﬂuorescence is decreased to similar extents,
approximately 66% within puriﬁed TC formed from Phe-
tRNAPhe(Cy3), GTP, and EF-TuQSY9, denoted TCQSY9/Cy3
(Supporting Information Figure S2a), and approximately 76%
within unpuriﬁed TC formed from Phe-tRNAPhe(Cy3), GTP,
and EF-TuAV‑Cy5, denoted TCAV‑Cy5/Cy3 (Supporting Informa-
tion Figure S2b), with both values determined after corrections,
as needed, for tRNA charging stoichiometry, EF-Tu labeling
stoichiometry, and partial Phe-tRNAPhe(Cy3) dissociation from
TC in dilute solution (see Supporting Information). The latter
value (76%) is essentially identical to the FRET eﬃciency
(74%) obtained for EF-TuAV‑Cy5 interaction with a Cy3
derivative of Phe-tRNAPhe labeled at position 47.22 The
similarity in the FRET eﬃciency values for TCQSY9/Cy3 and
TCAV‑Cy5/Cy3 is expected based on the similar Förster Ro values
for the pairs Cy3/QSY9 (55 Å)26 and Cy3/Cy5 (55−60 Å).27
Fluorescence quenching within TCQSY9/Cy3 is due solely to the
Figure 2. Fluorescence assays of TC interaction with 70SIC. (a−d) Labeled TC interaction with 70SICCy3 (Tu-L11 assay). (a) Cartoon showing
placement of labels. Cy3 ﬂuorescence intensity decreases on TCQSY9 binding to the A/T-site and increases on accommodation of tRNA into the A-
site and dipeptide formation. (b) Changes of 70SICCy3 ﬂuorescence on rapid mixing with TCQSY9 (black); in the presence of kirromycin
(precombined with 70SICCy3, red); with GDPNP in place of GTP (green). Very little change in ﬂuorescence is seen with wt-EF-Tu labeled at a
background level with QSY9 (light blue) or when mRNA is omitted (dark blue). Final concentrations: 70SICCy3, 0.1 μM; TCs, 0.4 μM; kirromycin,
100 μM; GDPNP, 250 μM. (c and d) Changes of Cy3 and Cy5 ﬂuorescence intensities, respectively, on rapid mixing of 70SICCy3 with TCAV‑Cy5
(black); in the presence of kirromycin (precombined with 70SICCy3, red); with GDPNP in place of GTP (green). Final concentrations: 70SICCy3,
0.1 μM; TCs, 0.4 μM; kirromycin, 100 μM; GDPNP, 1 mM. (e−g) Interaction of double−labeled TC with 70SIC (Tu-tRNA assay). (e) Cartoon
showing placement of labels. Cy3 ﬂuorescence intensity increase occurs on EF-Tu dissociation from the ribosome. (f and g) TCQSY9/Cy3 [(f) 0.1 μM]
or TCAV‑Cy5/Cy3 [(g) 0.1 μM] was rapidly mixed with 70SIC (0.4 μM) and Cy3 ﬂuorescence was monitored (black); in the presence of kirromycin
(precombined with 70SIC, red); with GDPNP in place of GTP (green). When GDPNP replaced GTP, adding kirromycin had no eﬀect (data not
shown). Final concentrations: kirromycin, 100 μM; GDPNP, 250 μM for TCQSY9/Cy3 and 1 mM for TCAV‑Cy5/Cy3, respectively.
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QSY9 bound at position 348, since added wt-EF-TuQSY9, which
lacks QSY9 bound at EF-Tu position 348 (Supporting
Information Table 1), has no eﬀect on Phe-tRNAPhe(Cy3)
ﬂuorescence (Supporting Information Figure S1c). Measuring
the rate of Phe-tRNAPhe(Cy3) quenching as a function of EF-
TuQSY9 concentration allowed estimation of a rate constant for
TC formation at 25 °C, kon, of 1.3 ± 0.1 μM
−1 s−1 (Supporting
Information Figure S2c). This is consistent with a previous
estimate for kon for unmodiﬁed EF-Tu of 0.11 μM
−1 s−1,
measured at 4 °C,28 assuming about a 10-fold increase in rate
for a 21° increase in temperature.
Two Stopped-Flow FRET Assays (Tu-L11; Tu-tRNA) of
PRE Complex Formation. The Tu-L11 assay (Figure 2a)
involves rapid mixing of 70SIC containing Cy3-labeled L11,
denoted 70SICCy3, with either TCQSY9 (Figure 2b) or TCAV‑Cy5
(Figure 2c and d). In each case, such mixing results in a
biphasic change in Cy3 ﬂuorescence, with an initial decrease
corresponding to TC binding to the ribosome that places EF-
Tu position 348 in proximity to L11 position 87, followed by a
restoration of ﬂuorescence intensity as these two positions
move apart (Figure 2b and c), with EF-Tu still bound to the
ribosome or fully dissociated from it. For TCAV‑Cy5 the expected
reciprocal changes are seen in Cy5 ﬂuorescence (Figure 2d).
These changes are completely dependent on the presence of
mRNA, with barely any change observed when mRNA is
omitted (Figure 2b, blue curve). Further, addition of wt-TCQSY9
has virtually no eﬀect on Cy3 ﬂuorescence (Figure 2b, cyan
curve), showing that the observed eﬀects of TCQSY9 on Cy3-
L11 ﬂuorescence are due solely to the QSY9 bound at EF-Tu
position 348, paralleling the results found with Phe-
tRNAPhe(Cy3) (Supporting Information Figure S1c).
The Tu-tRNA assay (Figure 2e) involves rapid mixing of
unlabeled 70SIC with either TCQSY9/Cy3 or TCAV‑Cy5/Cy3. In
each case, an increase in Cy3 ﬂuorescence resulted (Figure 2f
and g), ultimately leading to a complete loss of FRET
interaction between labeled tRNA and labeled EF-Tu
(Supporting Information Figure S3). This corresponds most
probably to EF-Tu·GDP release from the ribosome, but, as
above, could also reﬂect EF-Tu bound to the ribosome in a
position far removed from tRNA.
The curves obtained with both FRET assays were ﬁt to eq 1,
giving the k1app and k2app values listed in Table 2. These values
indicate that, following cognate TC binding to the 70SIC and
prior to the release of EF-Tu from the ribosome as EF-
Tu.GDP, EF-Tu moves away from the GAC, as measured by
k2app in the Tu-L11 assay, somewhat faster (1.5−3-fold) than
EF-Tu moves away from aa-tRNA, as measured by k1app in the
Tu-tRNA assay. Alternatively, the relatively small diﬀerence in
these two apparent rate constants could be a consequence of
using diﬀerent ﬂuorescent components in the two assays. In
either case, the similarity in the values is consistent with a
branched mechanism for the two movements (Figure 3,
pathways 1 and 2), a point we return to below.
Formation of Stalled Complexes. Adding kirromycin or
replacing GTP with the nonhydrolyzable analogue GDPNP
results, in both cases, in formation of a stalled complex, in
Table 2. Kinetic Parameters for 70SIC Interaction with TCa
assayb TC conditionsc k1app, s
−1 k2app, s
−1 A1/A2
d
Tu-L11 TCQSY9 standard 26 ± 4 6.2 ± 0.3 −1.0 ± 0.1
TCAV‑Cy5 19 ± 1 3.4 ± 0.3 −1.0 ± 0.1
TCAV‑Cy5,e 16 ± 1 3.7 ± 0.1 −1.0 ± 0.1
Tu-tRNA TCQSY9/Cy3 2.1 ± 0.3 0.31 ± 0.05 1.5 ± 0.4
TC AV‑Cy5/Cy3 2.1 0.33 1.3
Stalled Ribosomes
Tu-L11 TCQSY9 +kirromycin 35 ± 1 3.0 ± 0.7 1.1 ± 0.4
TCAV‑Cy5 25 ± 6 2.5 ± 0.4 0.7 ± 0.4
TCAV‑Cy5,e 20 ± 5 2.5 ± 0.1 0.7 ± 0.3
Tu-tRNA TCQSY9/Cy3 5.1 ± 0.8 1.1 ± 0.2 0.7 ± 0.3
TC AV‑Cy5/Cy3,e 2.3 0.58 0.6
Tu-L11 TCQSY9 GDPNP replaces GTP 5.1 ± 0.2
TCAV‑Cy5 3.3 ± 0.2
TCAV‑Cy5,e 3.8 ± 0.3
Antibiotic Eﬀects on tRNA Misreadingc
Tu-L11 TCQSY9 near-cog 24 ± 6 <0.07
Tu-tRNA TCQSY9/Cy3 0.74 ± 0.02 0.04 ± 0.01 0.19 ± 0.01
Tu-L11 TCQSY9 +STR 22 ± 2 3.0 ± 0.2 −1.4 ± 0.1
Tu-tRNA TCQSY9/Cy3 0.94 ± 0.04 0.13 ± 0.02 0.4 ± 0.1
Tu-L11 TCQSY9 +PAR 17 ± 3 2.5 ± 0.1 −1.7 ± 0.4
Tu-tRNA TCQSY9/Cy3 1.4 ± 0.1 0.22 ± 0.01 1.2 ± 0.2
Tu-L11 TCQSY9 near-cog+STR 32 ± 1 1.0 ± 0.3 −1.5 ± 0.5
Tu-tRNA TCQSY9/Cy3 1.1 ± 0.3 0.15 ± 0.04 0.3 ± 0.2
Tu-L11 TCQSY9 near-cog+PAR 23 ± 2 1.6 ± 0.4 −2.2 ± 0.8
Tu-tRNA TCQSY9/Cy3 0.89 ± 0.10 0.15 ± 0.06 0.5 ± 0.1
aValues shown are average ± average deviation of 2−4 independent determinations. Abbreviations: STR, streptomycin; PAR, paromomycin; near-
cog, near-cognate. bTu-L11 reactions were carried out using 0.1 μM 70SIC and 0.4 μM TC; Tu-tRNA reactions were carried out using 0.4 μM
70SIC and 0.1 μM TC. Unless otherwise indicated, reactions were monitored by changes in Cy3 ﬂuorescence. cStandard conditions included the use
of cognate codon and EF-Tu.GTP, and the absence of added antibiotic. Variations included substituting GDPNP for GTP or near-cognate codon for
cognate codon, and/or adding an antibiotic at a ﬁnal concentration of 100 μM. dRatio of the apparent amplitudes in eq 1. eMonitored by changes in
Cy5 ﬂuorescence.
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which EF-Tu is held on the ribosome.29,30 As seen using the
Tu-L11 assay, these stalled complexes form at diﬀerent rates,
but display similar (Figure 2b) or essentially identical (Figures
2c and d) high FRET eﬃciencies, as measured with TCQSY9 or
TCAV‑Cy5, respectively. The FRET eﬃciency with TCAV‑Cy5 is
equal to 0.55, as determined from the spectral data presented in
Supporting Information Figure S4, corresponding to a Cy3-Cy5
distance of 58 Å. This is in reasonable accord with the predicted
Cα: Cα distance of 40 Å (Figure 1) and the added distance to be
expected between the two ﬂuorophores attached via tethers to
these positions. In contrast, the stalled complexes have quite
diﬀerent EF-Tu:tRNA FRET eﬃciencies (Figure 2f and g),
with GDPNP completely blocking the increase in Cy3
ﬂuorescence in the Tu-tRNA assay, whereas added kirromycin
permits a 50−60% increase, corresponding to an ∼13−18 Å
increase in the tRNA:EF-Tu distance. These results indicate
that GDPNP fully blocks both pathways described in Figure 3,
whereas kirromycin only fully blocks pathway 1, permitting
partial separation of EF-Tu from aminoacyl-tRNA via the ﬁrst
step of pathway 2, while maintaining the EF-Tu:L11 distance
giving rise to high FRET eﬃciency.
The results presented in Figure 2 show an apparent
inconsistency with high resolution X-ray structures of
kirromycin- and GDPCP-stalled ribosomes containing bound
EF-Tu, which display no signiﬁcant diﬀerences in the distance
of EF-Tu (position 348) to either L11 (position 87) or aa-
tRNA (D loop).6,7,31 We speculate that this apparent
inconsistency arises from the conformational mobility of the
kirromycin-stalled complex, as has been demonstrated in
cryoelectronmicroscopy studies.16,21 These studies have iden-
tiﬁed 4−6 structurally distinct kirromycin-stalled complexes,
and revealed especially high disorder in the D-loop region of
the aa-tRNA, which is the site of Cy3 labeling in our
experiments. Such conformational mobility will give rise to a
measured EF-Tu:tRNA FRET value that reﬂects an averaging
of all the structural states present in solution. In contrast, the X-
ray structure determinations were each carried out on
essentially a single conformational state that was present in
the crystals. Alternatively, or in addition, it is possible that there
Figure 3. Branched mechanism for EF-Tu movement away from both
the GAC (L11) and aa-tRNA following GTP hydrolysis that
culminates in EF-Tu dissociation from the ribosome. Solid red lines
indicate high FRET eﬃciencies between aa-tRNA and L1119 and
between EF-Tu and both aa-tRNA and L11 (this work). The latter two
are lost during PRE complex formation. Pathway 1 is slightly preferred
for cognate codon. Kirromycin blocks the ﬁrst step of pathway 1 and
the second step of pathway 2, leading, in the latter case, to a partial
distancing of EF-Tu from aa-tRNA, and lower FRET, as indicated by
the dotted line.
Figure 4. tRNA selectivity demonstrated by (a) TCQSY9 eﬀects on the ﬂuorescence of 70SICCy3 (Tu-L11 assay see Figure 2a) or (b) 70SIC eﬀects on
the ﬂuorescence of TCQSY9/Cy3 (Tu-tRNA assay see Figure 2e). Cognate mRNA (UUU, black); near-cognate mRNA (CUC, red); near-cognate
mRNA, high TC concentration (CUC, cyan); noncognate mRNA (CGU, green); without mRNA (blue). In part a, no further ﬂuorescence changes
are seen out to 3 s. Parts c and d repeat the assays shown in parts a and b, respectively, in the presence of aminoglycoside antibiotics. Cognate
mRNA, no antibiotic (black); cognate mRNA, STR (green); cognate mRNA, PAR (blue); near-cognate mRNA, no antibiotic (red); near-cognate
mRNA, STR (cyan); near-cognate mRNA, PAR (lavender). Final concentrations: 70SICCy3 in a, 0.1 μM; 70SIC in b, 0.4 uM; TCQSY9 in a, 0.4 μM;
high concentration, 1.0 μM; TCQSY9/Cy3 in b, 0.1 μM; STR, 100 μM; PAR, 100 μM.
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are signiﬁcant structural diﬀerences between complexes stalled
with GDPNP, as in the present work, and complexes stalled
with GDPCP, employed in the structural studies. Such
diﬀerences have been reported between ribosome complexes
containing EF-G that are stalled with GDPCP or GDPNP.32,33
Antibiotic Eﬀects on tRNA Misreading. The Tu-L11 and
Tu-tRNA assays provide convenient methods for examining the
selectivity of TC binding to 70SIC programmed at the
decoding center with cognate (UUU) and near-cognate
(CUC) codons, and the ability of the misreading-inducing
aminoglycoside antibiotics streptomycin (STR) and paromo-
mycin (PAR)11,12,34−36 to modulate such selectivity. Prelimi-
nary experiments using the noncognate CGU codon showed
almost no change in Cy3 ﬂuorescence in either assay (Figures
4a and b) and were not pursued.
As measured in the Tu-L11 assay, reaction of TCQSY9 with a
70SICCy3 programmed with near-cognate CUC leads to a
monophasic decrease in Cy3 ﬂuorescence intensity, which
proceeds with a rate constant similar to that found for the ﬁrst
phase of TCQSY9 binding to 70SICCy3 programmed with
cognate UUU (Figure 4a, Table 2). The magnitude of the
intensity drop is somewhat lower than in the cognate case, but
it can be increased by raising the TCQSY9 concentration.
However, the second phase of reaction is inhibited at least 100-
fold, showing no detectable rise in Cy3 ﬂuorescence from 0.2 to
3 s. These results indicate that near-cognate TC binding closely
mirrors that of cognate TC binding to the A/T site, although
with somewhat lower aﬃnity, but that subsequent movement
away from the A/T site either does not occur or is extremely
slow, consistent with conclusions reached in earlier studies.34
Figure 5. Eﬀects of tRNAVal2B T-stem mutation. (a) TC formation. Increase in EF-TuCy3 (0.4 μM) ﬂuorescence intensity on rapid mixing with either
wt-Val-tRNAVal2B (red line) (0.1 μM) or its T1 variant (0.1 μM) (green line) in the presence of 0.5 mM GTP. Inset shows kapp dependence on EF-
TuCy3 concentration. Wt-EF-Tu labeled to background levels showed no ﬂuorescence change (black line). Although EF-TuCy3 had higher initial
ﬂuorescence, all traces are shown starting at the same ﬂuorescence for ease of comparison. (b) TC dissociation. Decrease in EF-TuCy3 ﬂuorescence
intensity on rapid mixing of TCs made with the indicated Val-tRNAVal2B variants [formed by premixing of EF-TuCy3(0.4 μM) with the Val-tRNAVal2B
(0.1 μM) variant in the presence of 0.5 mM GTP], with excess (8 μM) unlabeled EF-Tu. The traces shown are an average of two independent
determinations. (c) Cartoon showing placement of labels. Cy3 ﬂuorescence intensity decreases on TCQSY9 binding to the A/T-site. Accommodation
of Val-tRNAVal into the A-site and dipeptide formation leads to an increase in Cy3 ﬂuorescence and a decrease in tRNAfMet(prf) ﬂuorescence. (d and
e) Changes in Cy3 and prf ﬂuorescence on rapid mixing of 70SICCy3 (0.1 μM) containing fMet-tRNAfMet(prf) with TCs formed by combining EF-
TuQSY9·GTP (1.6 μM) with the indicated Val-tRNAVal2B variants (0.4 μM). Solid black lines are global ﬁts to Scheme 1 using the k values shown in
Table 3. (d) 0−1 s. (e) 0−20 s. Only results for the T1 variant are shown in part e, because the reactions of the wt and ψ variants are essentially
complete within 1 s. All concentrations are ﬁnal after rapid mixing. The more pronounced decrease in Cy3 ﬂuorescence in the phase 1 of the L11-
tRNA assay for the T1 variant as compared with the wt and ψ variants is due, at least in part, to phase 2 being so much slower than phase 1 (Table
3), leading to a transient buildup of C1.
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The rise in Cy3 ﬂuorescence in the Tu-tRNA assay using
near-cognate mRNA proceeds much more rapidly than in the
Tu-L11 assay, although it is slowed some 12-fold vis-a-̀vis
cognate mRNA, as estimated from the t1/2 values in Figure 4b.
Thus, for near-cognate mRNA, partial movement of aa-tRNA
away from EF-Tu can take place in the absence of any
movement of EF-Tu away from L11 (Figure 3, pathway 2, step
1), paralleling the results obtained with cognate-programmed
ribosomes in the presence of kirromycin (Figure 2).
Added STR essentially abolishes the marked diﬀerences seen
in the two assays for cognate vs near-cognate codons, by both
decreasing some of the apparent rate constants for cognate
codon (Tu-L11 assay, k2app; Tu-tRNA assay, k1app, k2app) and
increasing the value of these same rate constants for near-
cognate codon (Figure 4c and d, Table 2). PAR displays similar
eﬀects, although reaction with cognate codon remains some-
what faster. These eﬀects on rate constants are qualitatively
similar to those obtained in studies of the eﬀects of STR and
PAR on decoding speciﬁcity measured by other assays.34−36
More unexpected is the observation that each antibiotic
decreases the ﬂuorescence change within the initial complex
formed on TC binding during the ﬁrst phase of the Tu-L11
assay (Figure 4c). Since STR does not weaken cognate TC
binding,34 this result suggests that these antibiotics, which bind
to the 30S subunit, increase the average L11 to EF-Tu distance
in the 50S subunit, presumably via a structural change in the
30S subunit that is propagated to the 50S subunit.37 As X-ray
structures in the presence and absence of PAR show little
diﬀerence in the global conformation of EF-Tu on the
ribosome,7 such a distance change is more likely to arise
from changes in the L11 position, which is generally not well-
ordered in crystal structures.
Eﬀects of Altering EF-Tu:aa-tRNA Aﬃnity. Schrader et
al.38 have recently presented results leading to the conclusion
that the aﬃnities of aa-tRNAs for EF-Tu are constrained to be
uniform by their need to bind tightly enough to form the TC
but weakly enough to rapidly release from EF-Tu during
decoding. In that work, the aﬃnity of variant tRNAVal2Bs for EF-
Tu was altered by mutation of a portion of the aa-tRNA stem
that binds directly to EF-Tu. Their principal ﬁnding was that,
provided that suﬃcient EF-Tu was added to form TC, the rate
of dipeptide formation with a 70SIC was similar for tRNA
variants binding to EF-Tu·GTP up to 100 times more weakly
than wt, but that such activity fell oﬀ very quickly for variants
binding to EF-Tu more tightly than wt, despite their having
rates of ribosome-dependent GTP hydrolysis similar to that of
wild type.
Here, we re-examine this question at higher kinetic
resolution by determining the inﬂuence of aa-tRNA aﬃnity
for EF-Tu on the timing of L11-EF-Tu distance change, as
measured by the Tu-L11 assay, and on the rate of movement of
aa-tRNA from the A/T site into the A/A site, as measured by
changes in the ﬂuorescence of proﬂavin-labeled fMet-tRNAfMet
[denoted fMet-tRNAfMet(prf)], bound in the P-site of the
70SIC.23 In so doing, we compare measurements on TCs
formed by wt Val-tRNAVal2B and two variants, denoted T1 and
ψ, which bind to EF-Tu·GTP with much higher or slightly
lower aﬃnity compared to wt, respectively.38
We ﬁrst measured TC dissociation rates. The ﬂuorescence
intensity of EF-TuCy3·GTP increases on forming a TC with
each of the Val-tRNAVal2B variants. The second-order
association rate constant for the wt-transcript, determined by
measuring the apparent association rate constant as a function
of EF-TuCy3 concentration, is 0.74 ± 0.06 μM−1 s−1 (Figure 5a,
inset). Dissociation rate constants (kd) for all three variants
were determined from the time dependence of the decrease in
Cy3 ﬂuorescence when the labeled complex is mixed with a
large excess of unlabeled EF-Tu, under conditions where
dissociation of the labeled complex is rate limiting for formation
of unlabeled TC (Figure 5b), giving the relative values shown
in Table 3. Similar relative values of kd were obtained for the ψ
and T1 variants by Schrader et al.38 using a ribonuclease
protection assay (Table 3).
We next carried out the Tu-L11 assay with a 70SICCy3
containing fMet-tRNAfMet(prf) and programmed with mRNA
MVYF and the TCs formed by each of the three Val-tRNAVal2B
transcripts, which allowed simultaneous monitoring of the
changes in Cy3 and prf ﬂuorescence (Figure 5c−e). Both sets
of data could be globally ﬁt to the simpliﬁed Scheme 1, in
which initial second order binding of TC to form complex C1 is
followed by formation of complex C2. In this second step, the
movement of EF-Tu away from L11 and aa-tRNA accom-
modation into the A-site, measured by the increase in Cy3
ﬂuorescence intensity and the decrease in proﬂavin ﬂuores-
cence intensity, respectively, appear to proceed simultaneously.
Thus, both assays may be monitoring the same event, aa-tRNA
movement from the A/T to the A/A position.
+ → →70SIC TC C Ck k1 2
1 2
(Scheme 1)
Fitting the results of the Tu-L11 assay for the T1 variant
measured at diﬀerent TC concentrations to the phenomeno-
logical eq 1 showed that k1app and k2app were linearly dependent
or lacked dependence on TC concentration, respectively
(Supporting Information Figure S5), providing additional
support for Scheme 1.
The microscopic rate constants k1 and k2 resulting from
global ﬁtting of the results in Figure 5d to Scheme 1 (Table 3)
show that the tightened aa-tRNA binding to EF-Tu in the T1
variant has little eﬀect on the rate of C1 formation but markedly
Table 3. Rate Constants for tRNAVal2B Variants
aSequences show portion of T-stem (boxed): top line, nts 65−63;
bottom line, nts 49−51. bValues are from this work, measured at 25
°C, unless otherwise speciﬁed. Measurements were performed in
duplicate or triplicate, with average deviations indicated. cThis work.
Value for wt is 0.039 s−1. The increase of ∼30-fold from the value
measured at 4 °C (see below) is consistent with the high ΔH† for this
reaction.36 dDissociation rate constant, 4 °C. Value for wt is 0.0013
s−1, as reported.36 eRate constants for Scheme 1, determined for
reaction of TCQSY9 with 70SICCy3 containing fMet-tRNAfMet(prf).
70SIC has the cognate codon for tRNAVal2B, GUC, in the A-site. fThe
overall rate constant for formation of the C2 complex ( Scheme 1)
= +k k k k k[TC] /( [TC] )ov 1 2 1 2 gThe rate constant for dipeptide
formation, measured at 20 °C, as reported.36
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decreases, by almost 2 orders of magnitude as compared with
the wt and ψ variants, the rates of EF-Tu movement away from
L11 and of tRNA movement into the A-site that accompany C2
formation. Moreover, allowing for some small diﬀerences in
experimental conditions, for each of the three variants there is
fairly close agreement between the overall rate constant for
complex C2 formation (kov) and the rate constant for dipeptide
formation (kdipep) measured by Schrader et al.
38 We conclude
that the decreased rate of dipeptide formation previously
measured for the T1 variant38 is not an eﬀect on the dipeptide
formation step itself nor on the rate of TC binding to the
ribosome, but rather reﬂects a speciﬁc inhibitory eﬀect on the
rate of movement of aa-tRNA from the A/T site to the A/A
site, which is accompanied by movement of EF-Tu away from
the GAC. At present it is unclear whether these two
movements are necessarily tightly coupled, or whether both
rates are equal because they depend upon a common rate-
determining step, e.g., release of tRNA from EF-Tu.
■ CONCLUDING COMMENTS
Here we present two new FRET assays for determining the
dynamics, during PRE complex formation, of movements
separating EF-Tu from either ribosomal protein L11, located
within the GAC (Tu-L11 assay), or from aa-tRNA (Tu-tRNA
assay). These assays utilize TCs formed from EF-Tu variants
labeled at position 348 with either a ﬂuorophore or a
ﬂuorescence quencher and either unlabeled or ﬂuorescent-
labeled aminoacyl-tRNAs. Application of these assays, in
conjunction with related measurements, has led to two new
mechanistic insights concerning PRE complex formation. First,
that although for wt-tRNA and cognate codon, both separation
movements occur at similar rates, with the L11 movement
proceeding a little faster, the two movements can be completely
decoupled from one another, either when a near-cognate codon
is employed, or in the presence of kirromycin. Second, that the
large slowdown in PRE complex formation resulting from
increasing EF-Tu aﬃnity for aminoacyl-tRNA arises from a
speciﬁc inhibitory allosteric eﬀect on the rate of movement of
EF-Tu away from the GAC, which accompanies the movement
of aa-tRNA from the A/T site to the A/A site.
Lastly, we wish to stress the clear potential of the Tu-L11 and
Tu-tRNA assays for screening new misreading-inducing
antibiotic candidates in high-throughput formats, given the
large changes in ﬂuorescence in these assays that are sensitive
to antibiotic addition (Figure 4). Such screening eﬀorts are of
fundamental importance, given the rise of resistance to
antibiotics currently in use,39 and the fact that the translational
apparatus of the bacterial cell remains one of the principal
targets of antibiotics for the clinical treatment of infection
worldwide.12
■ METHODS
Materials. The following materials were purchased from the
indicated suppliers: IPTG, GDP, GTP, GDPNP [guanosine 5′-[β,γ-
imido]triphosphate trisodium salt hydrate], TCEP [tris(2-
carboxyethyl)phosphine hydrochloride], streptomycin, paromomycin,
kirromycin, and poly(U), bulk E. coli tRNA, amino acids (Sigma);
Talon Superﬂow Metal Aﬃnity Resin (Clontech); plasmid pTZ18R
(Amersham); QSY9 maleimide, dNTP, and Top 10 competent cells
(Invitrogen); Cy3 maleimide, Cy5 maleimide, NAP-5 column, pGEX
vector, MonoQ column (GE Healthcare); pET-15b vector (Novagen);
QuikChange site-directed mutagenesis kit (Stratagene); phosphoe-
nolpyruvate (PEP), pyruvate kinase (PK), and RNase A (Roche);
proﬂavin (MB Biomedicals); inorganic pyrophosphatase, Phusion
DNA polymerase and DpnI (New England Biolabs); PCR puriﬁcation
kit (QIAGEN); Amicon Ultra ultraﬁltration units and nitrocellulose
ﬁlters (Millipore); GF/C ﬁlters (Whatman); E. coli tRNAfMet and yeast
tRNAPhe (Chemical Block, Moscow).
Tightly coupled wild-type 70S ribosomes from E. coli MRE600 cells,
mutant 70S ribosomes lacking L11 from E. coli AM77 cells, cloned E.
coli His-tagged proteins (IF1-3, L11(C38S/S87C), and EF-G), and
mRNA 022 and 022CUC were prepared and puriﬁed as previously
reported.23 mRNA MVYF was prepared by mutation of the mRNA
022 sequence via PCR,40 using the following primers: forward, 5′-TTA
ACT TTT AAA TTT TTG AAT TCC CTA TAG TGA GTC GTA
TTA AAT TC-3′; over-reverse, 5′-CAG GTA TAC ATA CTA TGG
TCT ACT TTA CTA CGA TCT TCT TCA CTT AAC GCG TCT
GCA GGC ATG-3′; reverse, 5′-CTT CAC TTA ACG CGT CTG
CAG GCA TG-3′; over-forward, 5′-AAG ATC GTA GTA AAG TAG
ACC ATA GTA TGT ATA CCT GTT AAC TTT TAA ATT TTT
GAA TTC CCT ATA GTG AGT CGT ATT AAA TTC-3′. For
mRNA MRFF, the corresponding coding sequence (underlined) with
a T7 promoter sequence (GGG AAT TCG AAA TAG AAG TCT
TCT TTT TGG A AAA ATT TAA AAG TTA ATA AGG ATA CAT
ACT ATG CGT TTC TTC CGT TTC TTC CGT AAA TTC CGT
GTG CGT TTT TTC AAA TTT GTG TTC CGT TAA CGC GTC
TGC AGG CAT GCA AGC TAA AAA AAA AAA AAA AAA AAA
AAA AAA GCT T), purchased from IDT, was ligated into plasmid
pTZ18R for expression and puriﬁcation.41 tRNAVal2B and mutants
were prepared by in vitro transcription as previously described.38 L11
labeling with Cy3 and the reconstitution of 70S ribosomes containing
L11Cy3 (70SCy3) were performed as described.19
Procedures described in Pan et al. (2007)42 were used to
formylaminoacylate or aminoacylate tRNAfMet from E. coli or tRNAPhe
from yeast, respectively, and to prepare fMet-tRNAfMet(prf), except
that, in the latter case, tRNAfMet was reduced with NaBH4,
aminoacylated and puriﬁed on FPLC (MonoQ) ﬁrst, then labeled
with prf. tRNAPhe was labeled with Cy3 at positions 16 and 1743 and
tRNAVal2B transcripts were aminoacylated44 as previously reported.
Bulk aa-tRNAs from E. coli were prepared by charging bulk E. coli
tRNAs with 19 amino acids (-Cys). The charging mixture contained
ATP (10 mM), each amino acid (0.3 mM), bulk tRNAs (50 μM), a
1:30 dilution of S100 from MRE600 cells as the source of aminoacyl-
tRNA synthetases, 0.0025 U μL−1 inorganic pyrophosphatase in buﬀer
(50 mM HEPES, pH 7.6, 30 mM KCl, 70 mM NH4Cl, 15 mM
MgCl2,). The reaction mixture was incubated at 37 °C for 30 min and
quenched by addition of a 1/10 volume of 3 M NaOAc (pH 5.2). tRNA
was precipitated by addition of 2.5 volumes of 96% (v/v) EtOH to
reaction mixture aliquots (4 °C). Pellets were washed with 75% (v/v)
EtOH and air-dried prior to use.
EF-Tu Variant Preparation and Labeling. C-terminal His-
tagged E-coli E348C-EF-Tu was prepared as previously described45
with the following changes. BL21 cells, transformed with a pET15b
EF-Tu plasmid, were grown in LB medium at 37 °C and harvested 5 h
after induction of protein expression by IPTG (1 mM). Cells (6 g)
were resuspended in buﬀer (50 mM Tris−HCl, pH 7.6, 60 mM
NH4Cl, 7 mM MgCl2, 7 mM 2-mercaptoethanol, 15 μM GDP, 15%
(v/v) glycerol) and were broken by French press. EF-Tu was puriﬁed
on a Co(II)-Sepharose (Talon) column (bed volume of 3 mL) and
stored in frozen aliquots (15 mg mL−1) in Buﬀer A (50 mM Tris-HCl,
pH 7.5, 100 mM NaCl, 10 mM MgCl2, 15 μM GDP). E348C-EF-Tu
labeling was carried out in Buﬀer A by incubating E348C-EF-Tu (0.8
mg, 0.1 mM), QSY9 or Cy3 maleimide (1.35 mM), and TCEP (1
mM) at room temperature (RT) for 6 h (ﬁnal volume, 150 μL). The
reaction was quenched by addition of β-mercaptoethanol (3 μL). The
mixture was diluted to 0.5 mL with Buﬀer A and loaded onto a NAP-5
column (0.5 mL) at RT to remove free QSY9. One mL of Buﬀer A
was used to elute the EF-Tu. Three fractions of volumes 200, 400, and
400 μL were collected. Labeled EF-Tu was eluted in the middle 400
μL.
The triple variant C137A/C255V/E348C-EF-Tu containing an N-
terminal GST-tag was constructed by inserting the tufa gene into the
pGEX vector and introducing site-speciﬁc mutations using the
QuikChange site-directed mutagenesis kit. In addition, a TEV protease
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recognition site was engineered between the GST and EF-Tu
sequences. The variant was puriﬁed as described,46 except that
bacterial cultures were grown in LB medium with 1 M sorbitol at 37
°C until A600 nm reached 0.6−0.8. Cells were induced with 1 mM IPTG
and EF-Tu expressed at 18 °C overnight. The GST tag was cleaved oﬀ
with recombinant TEV protease.47
Labeling reactions of EF-Tu were carried out at RT by forming TCs
with bulk aa-tRNAs from E. coli that protect Cys 81 from labeling, as
follows: EF-Tu (50 μM) was preincubated in labeling buﬀer (50 mM
HEPES-HCl, pH 7.6, 30 mM KCl, 70 mM NH4Cl, 7 mM MgCl2)
supplemented with GTP (1 mM), PEP (1 mM), pyruvate kinase (0.05
mg mL−1), and TCEP (100 μM) for 10 min, followed by addition of
bulk aa-tRNAs (200 μM) and additional incubation for 5 min. A 10×
excess of Cy5 maleimide was then added. The reaction mixture was
incubated for 6 h, quenched with β-mercaptoethanol (140 mM) and
loaded onto a 1 mL Mono Q column prewashed with labeling buﬀer
containing 15 μM GDP. EF-Tu was eluted with the labeling buﬀer
containing 0.25 M NaCl and concentrated using Amicon Ultra-15
ultraﬁltration units.
Functional Analysis of EF-Tu Mutants. EF-Tu interaction with
aa-tRNA was monitored by the ability of EF-Tu to protect aa-tRNA
against either RNase degradation or spontaneous deacylation. The
RNase protection assay was performed as described.23 Deacylation
reactions were performed in deacylation buﬀer (60 mM Tris-HCl, pH
7.8, 30 mM KCl, 30 mM NH4Cl, 3.1 mM Mg(OAc)2, 1 mM DTT, 1
mM PEP, 1 mM GTP, 0.05 mg mL−1 PK) containing 0.1 μM [14C]-
Phe-tRNAPhe (100 cpm/pmol) at 30 °C in the presence and absence
of 0.4 μM EF-Tu. Reactions were stopped at various time points with
400 μL ice-cold 10% (w/v) TCA/1.5% (w/v) Casamino acids
solution, the precipitate was collected on Whatman GF/C ﬁlters and
the radioactivity was determined.
The poly(Phe) assay was carried out in buﬀer (20 mM Tris-HCl,
pH 7.6, 200 mM NH4Cl, 10 mM MgAc2). Initiation complex was
made by mixing 70S ribosomes (0.3 μM), poly(U) (0.3 g L−1), [3H]-
AcPhe-tRNAPhe (0.36 μM) at 37 °C for 5 min. β-Mercaptoethanol (2
mM), PEP (0.4 mM), PK (4 mg L−1), GTP (0.5 mM), [3H]-Phe-
tRNAPhe (4.5 μM), and EF-G (0.5 μM) were then added, and the
mixture was fractionated into 6 μL aliquots. PolyPhe synthesis was
initiated by adding 0.5 μM of EF-Tu (2 μL) to the aliquots. After
incubation at 37 °C for 30 min, the reaction mixtures were quenched
with 0.3 mL of 5% (w/v) TCA, heated to 95 °C for 15 min and cooled
on ice for 1 h. Filter binding was performed using nitrocellulose ﬁlters
followed by three washes with 5% (w/v) chilled TCA, and
radioactivity was determined.
Testing of ﬂuorescence quenching eﬃciency was performed in
Buﬀer B (50 mM Tris-HCl, pH 7.5, 70 mM NH4Cl, 30 mM KCl, 7
mM MgCl2, and 1 mM DTT) supplemented with 100 μM GTP, 2
mM PEP and 10 μg mL−1 PK. 0.17 μM of Phe-tRNAPhe (Cy3) was
incubated with diﬀerent concentrations of free QSY9 or EF-TuQSY9
variants at 37 °C for 10 min.
Complex Preparation. All complexes were prepared in Buﬀer B at
37 °C. 70SICs and TCs were made as described,23 except that EF-Tu
was in 4-fold excess of tRNA unless otherwise speciﬁed. For
experiments using fMet-tRNAfMet(prf) or GDPNP, further puriﬁcation
of 70SIC was performed by centrifugation through a 1.1 M sucrose
cushion in Buﬀer B (Sorvall S120-AT2 rotor, 110 K rpm, 40 min, 4
°C). No PEP or PK was added when GDPNP was used. To evaluate
the quenching eﬃciency between EF-TuQSY9 and [3H]-Phe-tRNAPhe
(Cy3), TC [formed by combining 2 nmol of EF-TuQSY9 and 0.7 nmol
of Phe-tRNAPhe (Cy3)] was puriﬁed on a Co(II)-Sepharose (Talon)
resin (0.5 mL). TC and resin prewashed with Buﬀer C (Buﬀer B
minus DTT) were mixed with shaking at 4 °C for 30 min. Following
centrifugation, the resin was transferred to a small spin column.
Washing with 4 mL of Buﬀer C removed all forms of tRNAPhe not
bound within a TC. The wash step was followed by elution with 2 mL
portions of Buﬀer C containing 300 mM KCl and ﬁrst 10 mM
imidazole, and then 300 mM imidazole. 0.5 mL fractions were
collected. TC was eluted in the ﬁrst fraction of the 300 mM imidazole-
containing buﬀer.
Kinetic Experiments. Kinetic experiments were performed in
Buﬀer B at 25 °C. Stopped-ﬂow experiments were carried out on
KinTek SF-300X stopped-ﬂow spectroﬂuorometer. Cy3 was excited at
530 nm and monitored using either a 570 nm long-pass ﬁlter or a 570
± 10 nm band-pass ﬁlter for experiments in which proﬂavin
ﬂuorescence was monitored simultaneously. Proﬂavin was excited at
462 nm and monitored using a 515 ± 15 nm band-pass ﬁlter. Cy5
ﬂuorescence was monitored using a 680 ± 10 nm band-pass ﬁlter.
Apparent rate constants were obtained by exponential ﬁtting using
Origin (OriginLab). Fitting the Tu-L11 assay results clearly requires a
double exponential. Although the Tu-tRNA assay results could be
adequately ﬁt with a single exponential, superior ﬁts were obtained
using double exponentials (eq 1) (adjusted R2 values were 0.990−
0.993 for single exponential ﬁts and 0.999 for double exponential ﬁts).
= + +− −F F F e F ekt kt0 1 21app 2app (1)
Global ﬁttings to Scheme Scheme 1 were carried out using Scientist
(MicroMath Research). The fMetPhe-tRNAPhe formation was
measured using a rapid-quenched ﬂow assay as described.23 Final
concentrations: TCQSY9, 0.3 μM; 70SIC, 1.2 μM.
Steady-State Fluorescence. Samples were excited at either 530
nm (for EF-TuQSY9 experiments) or 514 nm (for EF-TuAV‑Cy5
experiments) at RT (Fluoromax-3, Jobin Yvon).
Calculation of Residue Surface Exposure. Calculations were
carried out within Pymol using the FindSurfaceResidues plug-in from
PyMOLWiki.org.
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